Ulrike Muscha Steckelings is a Professor of Integrative Pharmacology at the University of Southern Denmark, Odense, Denmark. She is a physician by training and received her MD from the University of Heidelberg, Germany. She worked as PostDoc at the Department of Pharmacology, University of Heidelberg, the Dept. of Medicine, University of Melbourne, Australia and the Dept. of Cardiovascular Research, Ciba Geigy, Basel,Switzerland. Muscha has a specialisation in Dermatology and a “habilitation” (Germanqualification comparable to an extended PhD) in Experimental Pharmacology from Charité– Medical Faculty, Berlin, Germany. Her research focuses on the angiotensin AT2-receptor and comprises studies ranging from receptor pharmacology and signalling to pharmacological studies in preclinical disease models to the involvement in the clinical development of the angiotensin AT2-receptor agonist C21. Muscha is past-President of the European Council for Cardiovascular Research, member of the Women in Research Committee of the International Society of Hypertension, member of the Editorial Board of Hypertension Research and Clinical Science and of the Steering Committee of the Gordon Research Conference on Angiotensin. She has been an invited speaker at international conferences on multiple occasions and is author of more than 90 peer-reviewed publications.